Prosecution Insights
Prosecution Insights
Technology area: Semiconductors, Circuits & Optics
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mylife Diabetes Care AG currently manages a company patent portfolio focused on the Semiconductors, Circuits & Optics technology area. The portfolio shows a concentrated prosecution environment, with 2 pending office actions distributed across 2 distinct examiners. This ratio between pending actions and examiners suggests that each official is currently handling a single active matter for the company.
The prosecution activity is further centralized within 1 distinct art unit. This indicates a narrow technical focus for the pending applications within the broader semiconductor field. ELSHAER, ALAAELDIN M is identified as the busiest examiner for this portfolio, currently responsible for 1 busiest examiner pending office action. Because this single action represents a portion of the 2 pending office actions, the examiner's individual throughput significantly impacts the portfolio's overall progression.
Practitioners should note that the presence of only 1 distinct art unit simplifies the landscape for monitoring examiner behavior and internal consistency. With only 2 distinct examiners involved, the company maintains a small footprint in the patent office for this specific technology area. The limited volume of pending office actions allows for a tailored strategy for each application, while the single art unit provides a uniform technical standard for the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELSHAER, ALAAELDIN M | 1 | 36.1% | +30.5% |
| NATHAN, AIDAN LUKE | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19252264 | CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE | ELSHAER, ALAAELDIN M | — |
| 18615390 | CANNULA ASSEMBLY FOR A WEARABLE DRUG DELIVERY DEVICE | NATHAN, AIDAN LUKE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19252264 | CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE | ELSHAER, ALAAELDIN M | — |
| Art Unit | Apps |
|---|---|
| 2857 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19252264 | CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE | ELSHAER, ALAAELDIN M | 2857 | §101§102§103Other | Non-Final OA | — | Pending | Jun 27, 2025 |
| 18615390 | CANNULA ASSEMBLY FOR A WEARABLE DRUG DELIVERY DEVICE | NATHAN, AIDAN LUKE | — | §102§103§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial